Canopy Health Innovations   Report issue

For profit Phase 2
Founded: Toronto ON Canada (2016)
Status: No NME R&D (2016)

Organization Overview

First Clinical Trial
2019
NCT03984604
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Canopy Health Innovations

Active Ingredients

Drugs in Phase 2 Trials (2)

cannabidiol (Epidiolex) (1 trial)

cannabis (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anxiety Disorders (Phase 2)

Phobia, Social (Phase 2)

Sleep Initiation and Maintenance Disorders (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2